Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy

Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.

Handshake of businessmen

More from Strategy

More from Business